Trial · NCT03419364
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Arterial Blood Pressure (MAP) | Baseline, 48 hours | mmHg | MEAN | |
| SECONDARY | Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN) | Within 24 hours of any dose, up to a maximum 4 weeks | Healthy women were not at risk for liver toxicity and therefore were not assessed for ALT. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN) | Within 24 hours of any dose, up to a maximum 4 weeks | Healthy women were not at risk for liver toxicity and therefore were not assessed for AST. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Maternal Side Effects | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Percentage of Women Maternal Abdominal Tenderness | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Women With Headache Unrelieved by Oral Analgesics | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | percentage of participants | NUMBER | |
| SECONDARY | Percentage of Women With Hematocrit Decrease of More Than 3% | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | Healthy women were not at risk for anemia and therefore were not assessed for Hematocrit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Women With Less Than 500 cc Urine Output in 24 Hours | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | Healthy women were not at risk for oliguria and therefore were not assessed for urine output. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Fetuses With Category III Non Stress Test Results | From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks | Healthy women were not at risk for placental insufficiency and therefore did not have a non stress test. | percentage of fetuses | NUMBER |
| SECONDARY | Percentage of Fetuses With Biophysical Profile < 6 | From initial administration of study agent until 24 hours post last dose | Data only collected if indicated and performed as part of clinical care. No primary care providers felt this test was indicated. | ||
| SECONDARY | Mean Peak Nicotinamide Level | at 1 hour post 1000 mg nicotinamide administration on Day 1 | Data reported for all participants who had blood collected. | ng/mL | MEAN |
| SECONDARY | Mean Trough Concentration Nicotinamide Administration | 8 hours after the 8 a.m. 1000 mg nicotimamide administration on Day 1 | Data reported for all participants who had blood collected. | ng/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03419364/outcomes